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Abstract
Background: The management of small, nonfunctioning pancreaticoduodenal endocrine tumors
(NFPET) in multiple endocrine neoplasia type 1 (MEN1) patients is still controversial. We therefore
investigated the effect of surgery on survival and tumor progression in MEN1 patients with NFPET
2 cm by analyzing data from the Groupe des Tumeurs Endocrines (GTE) registry.
Materials and Methods: Among 579 MEN1 patients in the registry, 65 had NFPET  2 cm. Fifteen
(23%) underwent pancreatectomy, 9 at least segmental pancreatectomies and 6 biopsies or
enucleations (the surgery group), and 50 (77%) were followed conservatively (the no surgery
group). Age at MEN1 and NFPET diagnosis was similar in both groups, as was size of the primary
tumor. Seven (10.8%) patients had metastases. Five metastases were synchronous, and 2 (one in
each group) were metachronous. Tumor size was similar in patients with or without metastasis.
Results: There was no perioperative mortality. The average follow-up time after NFPET diagnosis
was 6.7 years in the surgery group and 3.3 years in the no surgery group. Three (4.6%) patients
died during follow-up, 2 due to NFPET and 1 due to thymus tumor. The 2 patients who died of
NFPET had undergone pancreatic surgery at the time of NFPET diagnosis. The 2 groups did not
differ significantly with respect to tumor progression [5/15 (33%) vs 6/38 (16%), P = 0.16]. Overall
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life expectancy of patients with NFPET 2 cm was not different than that of the 229 MEN1
patients in the registry without any pancreaticoduodenal tumor (P = 0.33).
Conclusions: This study suggests that surgery may not be beneficial for MEN1 patients with
NFPET 2 cm.
The prevalence of nonfunctioning pancreaticoduode-nal endocrine tumors (NFPET) in patients with
multiple endocrine neoplasia type 1 (MEN1) is steadily
increasing as a result of earlier diagnosis after genetic
testing, better standardized follow-up care, and more
sensitive imaging studies for detecting pancreatic tumors.
NFPET are currently the most frequent pancreaticoduo-
denal tumors in MEN1 patients.1–4 In a recent study that
used prospective endoscopic ultrasonography in patients
diagnosed with MEN1, 55% had NFPET at an average
age of 39.5
Nonfunctioning NFPET are a significant cause of death
in MEN1 patients,4,6–9 and the consensus is that patients
with tumors greater than 2 or 3 cm should undergo
resection.2,10,11 However, pancreatic surgery is associ-
ated with significant mortality and morbidity,2,12–15 and
there is still controversy about the risk–benefit ratio of
surgery in patients with small (2 cm) NFPET.
We have previously shown that 27% of MEN1
patients with NFPET between 2.1 and 3.0 cm had syn-
chronous or metachronous metastasis whereas 11% with
tumor size 2 cm had metastasis.4 We thought an
approximately 10% risk of having or developing metas-
tasis could be considered clinically acceptable since the
mortality rate for pancreatic resection ranges from 3.8%
to 17.6%13 and the rate of long-term postoperative dia-
betes was 81% in MEN1 patients who underwent
aggressive surgery for pancreaticoduodenal tumors.12
We therefore chose a threshold of 2 cm in order to
investigate the effect of surgery on survival and tumor
progression in MEN1 patients with small NFPET.
PATIENTS AND METHODS
The Groupe des Tumeurs Endocrines (GTE; endocrine
tumor study group) was created in 2002 by the fusion of the
Groupe d’Etude des NEM1 (GENEM; study group on
MEN1) and the Groupe d’Etude des Tumeurs a` Calcitonine
et NEM2 (GETC; study group on calcitonin-producing
tumors and MEN2). One of the tasks of the GTE is to
maintain a registry of patients with MEN1. The registry,
which is maintained at the Center for Epidemiology of the
Population at the University of Bourgogne in Dijon, France,
is sent reports on MEN1 patients from the 2 French labo-
ratories accredited for genetic testing of MEN1 and pa-
tients’ physicians. Registry data for MEN1 patients
includes results of genetic testing, clinic visit reports,
operative reports, pathology reports, and hospital dis-
charge summaries.
As has been previously described,4 patients with NFPET
were identified among MEN1 patients included in the GTE
registry who were diagnosed from June 1956 to April 2003.
Briefly, NFPET was diagnosed when one or more
pancreatic solid nodules were evidenced by any imag-
ing studies and after excluding gastrinomas, insulino-
mas, glucagonomas, VIPomas or somatostatinomas.16,17
A total of 65 patients with NFPET2 cm were identified in
the registry. Patients were separated into a surgery group,
which consisted of those who underwent pancreatectomy,
and a no surgery group, which consisted of patients who
were followed conservatively (e.g., watchful waiting).
Penetrance of NFPET in the MEN1 population of the reg-
istry was estimated using the Kaplan–Meier method for 4
different time periods, according to MEN1 diagnosis date.
The dates for separating the 4 groups were chosen in order
to have 4 quartiles consisting of similar numbers of pa-
tients with NFPET: groups 1, 2, 3, and 4 were defined as
MEN1 diagnosis before 1989, between 1989 and 1994,
between 1995 and 1998, and after 1998, respectively.
Results are presented as mean values – standard
deviation (SD) unless otherwise stated. Comparisons
between groups were made using the chi-square test,
Fisher’s exact test, or Student’s t-test. Survival data were
analyzed using the Kaplan–Meier method, and groups
were compared using the log-rank test. P values <0.05
were considered statistically significant. Statistical anal-
yses and graphs were performed with SPSS software
version 11.0.1 (SPSS Inc., Chicago, IL, USA). Legends
and numbers of patients at risk were added on the graphs
using Adobe Photoshop Elements (Adobe Systems
Incorporated, San Jose, CA, USA).
RESULTS
Increasing Frequency of NFPET in MEN1
Patients Over Time
Over the 4 time periods, the percentage of patients with
NFPET increased steadily from 13.2% in group 1 to
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16.0% in group 2, 19.5% in group 3, and 31.4% in group
4. The estimated penetrance of NFPET in MEN1 patients
by age 40 increased over time and was 5.9% (95% CI:
2.1–9.6) in group 1, 7.5% (95% CI: 3.0–11.9) in group 2,
13.9% (95% CI: 7.0–20.7) in group 3, and 23.7% (95% CI:
12.9–34.4) in group 4 (Fig. 1). Moreover, over time,
NFPET was being diagnosed at a younger age, as shown
by the shift of the curves to the left side of the axis in
Fig. 1.
Patient Characteristics and Follow-Up
Of the 108 patients with isolated NFPET in the registry,
65 had tumors 2 cm. When we divided those patients
into 2 groups (surgery vs no surgery), they did not differ
significantly with respect to age, delay between MEN1
and NFPET diagnosis, and tumor size (Tables 1 and 2).
NFPET was diagnosed by imaging studies in 51 patients
(79%), by pancreatic polypeptide increase in 4 patients,
and by unknown means in 10 patients. Nearly 80% of
patients had multiple tumors. Patients in the surgery
group had more NFPET and more metastases (Table 2);
however, this may be due to the longer follow-up period
for that group (Table 3). Tumor size was similar in both
groups (Table 2) and in patients with or without metas-
tasis (1.30 – 0.35 cm vs 1.22 – 0.44 cm, P = 0.63). The
two patients who developed metachronous metastases
had primary tumors of 1.2 and 2.0 cm.
Fifteen patients underwent surgery for their NFPET.
Six underwent limited resection (biopsy or enucleation
only), and nine underwent at least a segmental pan-
createctomy (Table 4). There were no perioperative
deaths. Average follow-up time after NFPET diagnosis
was 6.7 years in the surgery group and 3.3 years in
the no surgery group. Three patients died during fol-
low-up: 2 following NFPET metastasis at age 39 and
57 several years after having undergone surgery at the
time of NFPET diagnosis (Table 4) and the third of a
thymus tumor at age 44. Although more patients in the
surgery group had disease progression or died than in
the no surgery group, the differences were not statis-
tically significant (Table 3). Finally, overall life expec-
tancy was similar for patients with NFPET 2 cm and
the 229 MEN1 registry patients who did not have
NFPET (Fig. 2). In this latter group, 8 died of MEN1-
associated lesions and 8 of diseases unrelated to
MEN1.
DISCUSSION
In this retrospective, registry-based study, we con-
firmed that the prevalence of NFPET among MEN1 pa-
tients increased over time. Moreover, we found that
MEN1 patients with small NFPET 2 cm did not have
shorter life expectancy than those who did not have any
Figure 1. Cumulative percentage of nonfunctioning
pancreaticoduodenal endocrine tumors (NFPET) by
age in multiple endocrine neoplasia type 1 (MEN1)
patients. Patients were separated into 4 groups
according to the date of MEN1 diagnosis: group 1
(<1989), group 2 (1989–1994), group 3 (1995–1998),
group 4 (>1998). The number of patients at risk at each
age is shown below the graph.
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pancreaticoduodenal tumors. We also found that the
proportion of patients with NFPET who had tumor pro-
gression or died did not differ significantly between those
who underwent surgery and those whose tumors were
managed conservatively.
Historically, lack of a clinical syndrome associated with
NFPET in MEN1 patients resulted in these tumors being
discovered very late, often when patients had a palpable
abdominal mass and lymph node and distant metasta-
ses. However, thanks to better knowledge of MEN1
Table 1.
Characteristics of the 65 multiple endocrine neoplasia type 1 (MEN1) patients with nonfunctioning pancreaticoduodenal
endocrine tumors (NFPET) 2 cm
No surgery group
(n = 50)
Surgery group
(n = 15) P value
Age at MEN1 diagnosis 35.6 – 13.0 36.0 – 15.4 0.97*
Time between MEN1 diagnosis and
NFPET diagnosis
6.1 – 5.4 6.7 – 9.1 0.78*
NFPET leading to diagnosis of MEN1 2 (4%) 1 (7%) 0.67**
Median date of NFPET diagnosis June 1999 January 1995
Associated MEN1 lesions
NFPET + para 15 (30%) 10 (67%)
NFPET + para + pit 15 (30%) 1 (7%)
NFPET + para + pit + adre 8 (16%) 7 (1%)
NFPET + para + adre 6 (12%) 2 (13%)
NFPET alone 2 (4%) 0
NFPET + pit 2 (4%) 0
NFPET + para + carc 1 (2%) 0
NFPET + para + carc + adre 1 (2%) 0
NFPET + carc 0 1 (7%)
Para: parathyroid; pit: pituitary; adre: adrenal; carc: carcinoid.
Results are mean – SD or values (percent).
*Student’s t-test.
**Chi-square test
Table 2.
Nonfunctioning pancreaticoduodenal endocrine tumor (NFPET) characteristics
No surgery
group (n = 50)
Surgery group
(n = 15) P value
Number of tumors 2.7 – 2.1 4.8 – 2.2 0.048*
Size of the biggest tumor 1.17 – 0.42 1.41 – 0.40 0.059*
Location 0.72**
Head 8 (16%) 4 (27%)
Body 7 (14%) 1 (7%)
Tail 7 (14%) 4 (27%)
Head + body + tail 6 (12%) 3 (20%)
Head + body 5 (10%) 0
Body + tail 4 (8%) 2 (13%)
Head + tail 2 (4%) 1 (7%)
N/A 11 (22%) 0
Presence of metastasis 3 (6%) 4 (27%) 0.044***
Lymph nodes 0 3 (20%)
Liver 3 (6%) 2 (13%)
Synchronous 2 (4%) 3 (20%)
Metachronous 1 (2%) 1 (7%)
N/A: information not available; presence of metastasis: denotes the number of patients with single or multiple metastases.
Results are mean – SD or values (percent).
*Student’s t-test.
**Chi-Square test.
***Fisher’s exact test.
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disease and to genetic testing available since 1997,
many patients in a familial setting of MEN1 are now
diagnosed on a genetic basis only and are then treated
using well-established protocols.11,18,19 These treatment
protocols always include pancreatic imaging studies,
which have become more sensitive during the last
decade. Endoscopic ultrasonography is currently the
most sensitive imaging study available for detecting
pancreatic lesions20–22 and can detect lesions as small
as 2 mm.5 Systematic use of sensitive pancreatic
imaging studies in patients diagnosed with MEN1 at a
younger age led to an increased recognition of NFPET
so that they have now become the most frequent pan-
creaticoduodenal lesions in patients with MEN1.1–3
Using the GTE registry data, we confirmed that the
frequency of NFPET progressively increased over the 4
time periods studied, with the biggest increase taking
place since 1998. Moreover, previous autopsy data
showing that more than 80% of MEN1 patients have
some pancreaticoduodenal tumors23 are now confirmed
by clinical studies, including 2 from the GTE showing
that 55% of MEN1 patients have pancreaticoduodenal
tumors at a mean age of 39 when endoscopic ultraso-
nography is used prospectively5 and that the estimated
cumulative frequency of pancreaticoduodenal tumor is
84% at age 80.4 Because NFPET represents a signifi-
cant cause of death in MEN1 patients, several groups
have proposed an aggressive approach to these tumors,
recommending excision of every tumor evidenced by
imaging studies or biochemically proven.1,3,8,12 How-
ever, this high frequency of NFPET leads to a new
clinical problem: whether all patients with MEN1 should
undergo pancreatectomy with the aim of preventing
cancer. This is controversial first because NFPET are a
significant cause of death in MEN1 patients, accounting
for 39% of the MEN1-related mortality but only for 15%
of overall mortality,9 far below the 55%–84% frequency
of pancreaticoduodenal tumors; second, because pan-
creatic surgery is associated with significant mortality
and morbidity (unlike prophylactic thyroidectomy in
MEN2); and third, because cancer prevention is not
totally achieved with less than total pancreatectomy.
In this study, each patient’s treatment was decided
upon by the physicians in charge of that patient and
did not follow specific recommendations. The fact that
primary tumor size was similar in the surgery group
and the no surgery group and that the median date of
NFPET diagnosis in the no surgery group was 4.5
years later than in surgery group suggests that phy-
sicians in charge of these MEN1 patients tended to be
less aggressive over time in how they treated tumors
2 cm. This tendency is further confirmed by the fact
that although 35 patients were newly diagnosed with
NFPET 2 cm since January 1999, only 2 underwent
surgery for their tumors. Our finding that patients in
the surgery group had more tumors and more
metastases is not surprising because preoperative
imaging studies always underestimate the extent of
disease, particularly the number of small pancreatic
tumors and lymph node metastasis, as other studies
have shown.24 Therefore, we think these differences in
the two groups represent the difference in detection
modality (pathology report versus imaging studies) and
not a true difference.
This study did not show any survival benefit for patients
with NFPET 2 cm who underwent surgery compared
with patients who had conservative management
(watchful waiting). Moreover, in the surgery group,
Table 3.
Follow-up of patients with nonfunctioning pancreaticoduodenal endocrine tumor (NFPET) 2 cm
No surgery group
(n = 50)
Surgery group
(n = 15) P value
Follow-up time (years) 3.3 – 2.6 6.7 – 4.0 0.001*
Progression/recurrence of
tumor [n/n at risk (percent)]
6/38 (16%) 5/15 (33%) 0.156**
Reoperation 0 1 (7%)
Deaths [n/n at risk (percent)] 1/38 (3%) 2/15 (13%) 0.190***
Related to NFPET 0 2 (13%)
Unrelated to NFPET 1 (3%) 0
Progression/recurrence of tumor and deaths: in the no surgery group, 12 patients were diagnosed with NFPET after January
1999 and had no follow-up data available in the registry; therefore 38 patients were at risk in this group.
Results are mean – SD or values (percent).
*Student’s t-test.
**Chi-Square test.
***Fisher’s exact test.
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progression or recurrence of NFPET was as frequent as
in the no surgery group, which suggests that surgery did
not prevent death or tumor recurrence in these patients.
Even though the follow-up period was shorter for patients
in the no surgery group, and even though the surgery
consisted of biopsy or enucleation only in 6 patients, the
numbers of deaths and recurrences observed make it
very unlikely that over a longer period, surgery would
have an advantage over conservative management.
However, because of the retrospective nature of this
study, and because we could not always find the reason
why a patient was operated on, it is possible that patients
in the surgery group were identified as having more
aggressive disease and that the 2 groups are, in fact,
different in terms of tumor aggressiveness. Nevertheless,
this study suggests that patients with small NFPET and
Figure 3. Proposed algorithm for detection and management of nonfunctioning pancreaticoduodenal endocrine tumors (NFPET) in
multiple endocrine neoplasia type 1 (MEN1) patients. H+P: history and physical examination; tailored biochemical screening:
according to signs and symptoms and following specific protocols; CgA: measurement of blood levels of chromogranin A; hPP:
human pancreatic polypeptide gastrin, insulin, glucagons; VIP: vasoactive intestinal peptide; SMS: somatostatin; ): negative; +:
positive; EUS: endoscopic ultrasonography; CT: computer tomography; MRI: magnetic resonance imaging; LN: lymph node, mets:
metastasis. (1) We do not recommend systematic dosage of hPP for NFPET diagnosis since its increase does not change the
management of those patients. (2) Because the risk of developing a new tumor ‡2 cm seems low in patients without any tumor at
first pancreatic imaging studies, some authors recommend an EUS every 5 years for the follow-up of those patients.
Figure 2. Kaplan–Meier graph comparing life
expectancy for multiple endocrine neoplasia type 1
(MEN1) patients with nonfunctioning
pancreaticoduodenal endocrine tumor (NFPET) 2 cm
with that of MEN1 patients without pancreaticoduodenal
tumor. The number of patients remaining at each age is
shown below the graph.
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without sign of tumor aggressiveness can safely be fol-
lowed without rapid growth of a known tumor or devel-
opment of new tumors or metastases. Because of the
short follow-up in this study, long-term studies are war-
ranted to confirm this approach.
This study suggests that NFPET can follow different
patterns: many patients present with pancreaticoduode-
nal tumors, but few develop aggressive disease leading
to death. Additional clinical, biologic, or genetic markers
of tumor aggressiveness are needed to better predict
which patients are at greater risk for death and which
will have stable disease for years or decades. In our
opinion, the only currently available markers for
aggressiveness are primary tumor size, rapid growth of
an existing tumor, or the new appearance of a lymph
node or distant metastasis. We therefore recommend
operating on patients with NFPET >2 cm, patients with
NFPET that increase by >5 mm in 1 year, and patients
with newly detected lymph node metastasis or distant
metastasis (Fig. 3). Endoscopic-ultrasonography-guided
fine-needle aspiration is available and can be used to
determine whether a suspicious lymph node is benign or
malignant.
This study has several limitations. First, the 2 groups
are not quite similar because more patients in the sur-
gery group than in the no surgery group were diagnosed
during earlier time intervals. However, age at MEN1
diagnosis, delay from MEN1 diagnosis to NFPET diag-
nosis, and size of the primary tumor were similar in both
groups, suggesting that both groups are comparable.
Second, the study was retrospective and multi-institu-
tional, and the patients were not randomly assigned to
one or the other group and were followed with different
protocols according to the timing of diagnosis and the
institution. Moreover, the type of operation was not al-
ways a left pancreatectomy with cephalic enucleation,
which would be the recommended procedure by the
Uppsala and Ann Arbor group.3,12 Because of the small
number of patients involved, a subgroup analysis of
patients after the Ann Arbor procedure was not per-
formed; however, the information on each individual
patient is given in Table 4. Third, the study has a rather
short follow-up considering the relative indolent evolution
of these tumors.
In conclusion, we believe that the risk–benefit ratio of
surgery versus conservative management of small, non-
growing NFPET in MEN1 patients is in favor of conser-
vative management. We therefore recommend that
physicians who treat patients with MEN1 follow the
algorithm for detection and management of NFPET
shown in Fig. 3.
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